Помощь в выявлении и лечении орфанных заболеваний

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Протокол NCT03361137
Описание
Ход выполнения
100%
28.06.2018
13.03.2020
Заболевания
Дата начала КИ
28.06.2018
Дата окончания КИ
13.03.2020
Организация, проводящая КИ
Genentech, Inc.
Фаза КИ
IV
Цель КИ
This Phase IV, multicenter study will evaluate whether participants with Hemophilia A (PwHA) with or without inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without additional prophylactic bypassing agents (BPA; for participants with inhibitors) or factor VIII (FVIII; for participants without inhibitors).
Количество пациентов
14

Новости и обновления